Lilly Highlights Advancements in its Oncology Portfolio with New Data at ESMO 2016
The presentations on pemetrexed, ramucirumab and necitumumab include data from a few of Lilly's immuno-oncology clinical collaborations with
Lilly's data at the ESMO 2016
- Tumor cell signaling: Therapies that target cell signaling to interrupt the communication system that enables cancer cells to coordinate their basic activities;
- Tumor microenvironment: Treatments attacking the tumor microenvironment which work by reducing the flow of nutrients and mitogens that support and feed tumor cells; and
- Immuno-oncology: Therapies that use the patient's own immune system to fight cancer.
"Lilly's three-pillar oncology R&D strategy is unique," said
Select studies, along with the times and locations of their data sessions, are highlighted below.
Abemaciclib
- Abstract Title: Interim results from neoMONARCH: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR+/HER2- breast cancer (BC)
- Abstract #: LBA13; Proffered Paper session:
Friday, October 7 , 16:00 -17:30 CEST - Author/Speaker:
Sara Hurvitz , M.D.,UCLA Jonsson Comprehensive Cancer Center - Location/Room:
Stockholm
- Abstract #: LBA13; Proffered Paper session:
- Abstract Title: Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR+) HER2- metastatic breast cancer (MBC)
- Abstract #: LBA12; Poster Discussion session:
Sunday, October 9 , 16:30 -17:30 CEST - Author/Speaker:
Sara M. Tolaney , M.D., MPH,Dana-Farber Cancer Institute - Location/Room:
Berlin
- Abstract #: LBA12; Poster Discussion session:
Immuno-Oncology Collaborations with Pemetrexed, Ramucirumab and Necitumumab
- Abstract Title: Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
- Abstract #: LBA46_PR; Presidential Symposium session:
Sunday, October 9 , 16:25 -18:20 CEST - Author/Speaker:
Corey Langer , M.D.,University of Pennsylvania - Location/Room:
Copenhagen
- Abstract #: LBA46_PR; Presidential Symposium session:
- Abstract Title: Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
- Abstract #: LBA38; Poster Discussion session:
Monday, October 10 , 09:30 -10:30 CEST - Author/Speaker:
Roy S. Herbst , M.D., Ph.D.,Yale Cancer Center - Location/Room:
Berlin
- Abstract #: LBA38; Poster Discussion session:
- Abstract Title: Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): A phase 1b expansion cohort study
- Abstract #: 1260P; Poster Display session:
Saturday, October 8 , 13:00 -14:00 CEST - Author/Speaker:
Benjamin Besse , M.D., Ph.D., Institut d'Oncologie Thoracique - Location/Room: Hall E
- Abstract #: 1260P; Poster Display session:
Olaratumab
- Abstract Title: Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients
- Abstract #: 1402PD; Poster Discussion session:
Monday, October 10 , 11:00 -12:00 CEST - Author/Speaker: Robin L.
Jones , BSc, MB, MRCP, M.D.,Fred Hutchinson Cancer Research Center - Location/Room:
Brussels
- Abstract #: 1402PD; Poster Discussion session:
- Abstract Title: ANNOUNCE 2: An open-label phase 1b, and a randomized, double-blind phase 2 study of olaratumab with gemcitabine plus docetaxel in the treatment of patients with advanced soft tissue sarcoma (STS)
- Abstract #: 1420TiP; Poster Display session:
Monday, October 10 , 13:00 -14:00 CEST - Author/Speaker:
Andrés Redondo , M.D., Hospital Universitario La Paz - Location/Room: Hall E
- Abstract #: 1420TiP; Poster Display session:
Prexasertib
- Abstract Title: A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)*
- Abstract #: 855O; Proffered Paper session:
Friday, October 7 , 14:00 -15:30 CEST - Author/Speaker:
Jung-min Lee , M.D.,Center for Cancer Research ,National Cancer Institute ,National Institutes of Health - Location/Room:
Oslo
- Abstract #: 855O; Proffered Paper session:
Ramucirumab
- Abstract Title: Ramucirumab (RAM) as a second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
- Abstract #: 617PD; Poster Discussion session:
Saturday, October 8 , 08:00 -09:00 CEST - Author/Speaker:
Takuji Okusaka , M.D.,National Cancer Center Hospital - Location/Room:
Copenhagen
- Abstract #: 617PD; Poster Discussion session:
- Abstract Title: A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
- Abstract #: 710TiP; Poster Display session:
Saturday, October 8 , 13:00 -14:00 CEST - Author/Speaker:
Andrew X. Zhu , M.D., Ph.D.,Massachusetts General Hospital Cancer Center - Location/Room: Hall E
- Abstract #: 710TiP; Poster Display session:
*This presentation on prexasertib includes data from an investigator-initiated trial sponsored by the
About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly's commitment to people with cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. (P-LLY)
Lilly Forward-Looking Statement
This press release contains "forward-looking statements" (as that term is defined in
Refer to: |
|
|
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-highlights-advancements-in-its-oncology-portfolio-with-new-data-at-esmo-2016-300339515.html
SOURCE
News Provided by Acquire Media